|
|
|
|
|
|
|
NsGene develops novel biological products
for the treatment of neurological diseases to improve the lives of millions of people around the world as there are vast unmet needs in this market.
NsGene was founded in December 1999 as a spin-off from NeuroSearch A/S [OMX CPH: NEUR]. Since its inception, the Company has been working with leading research and development teams in biopharmaceutical companies and academic institutions to solve the issue of delivering protein factors across the blood-brain-barrier and to identify novel neurotrophic proteins with therapeutic effects in the nervous system.
|
|
|
|
|
|
R&D Programs
NsGene is committed to developing novel biologics for the treatment of neurological diseases and NsGene’s R&D activities are focused on a proprietary encapsulated cell biodelivery technology and proprietary neurotrophic proteins. Based on the EC BiodeliveryTM platform, NsGene develops implantable medicinal products that secrete therapeutic agents to the central nervous system to treat neurological diseases with high needs for efficacious treatments, including Alzheimer’s disease, Parkinson’s disease, and intractable epilepsy. To fuel the product pipeline, NsGene has generated a factor pipeline of neurotrophic proteins, which have the potential to become novel CNS therapeutics that can be administered to patients as an EC Biodelivery™ product or as an injectable protein formulation. |
|
|
NsGene and Biogen Idec sign new commercialisation and license agreement on Neublastin. Read more.
|
|
|
|
|
|
NsGene presents a number of interesting partnering opportunities within its product candidates and technology platform. Read more |
|
NsGene was spun off from NeuroSearch A/S in 1999 and is financed by institutional investors. NsGene is open for investments by new investors. Read more |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
